Prestige Brand Holdings Inc (PBH)

Nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops have been recalled due to potential contamination and "lack of assurance sterility." The Class II recall, initiated by Prestige Brand Holdings, affects lot 2552A of 15ml bottles with an expiration date of September 30, 2027. These eye drops were distributed nationwide at major retailers including Walmart, Kroger, and Target, and consumers are advised to stop using them and return them for a refund.

Nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops have been voluntarily recalled across the US by Prestige Brand Holdings due to concerns about a "lack of assurance of sterility." The FDA classified this as a Class II recall, indicating a moderate risk of temporary or medically reversible adverse health consequences. Consumers are advised to stop using the recalled product, which covers specific lot codes and expiration dates, and return them for a refund.

Prestige Brand Holdings is voluntarily recalling nearly 40,000 bottles of its Clear Eyes Maximum Itchy Eye Relief eye drops across the nation. The recall is due to a "lack of assurance of sterility" and is classified as a Class II recall by the FDA, indicating that use of the product may cause temporary or medically reversible adverse health consequences. The affected bottles have lot code 2552A and an expiration date of September 30, 2027.

Great Lakes Advisors LLC has acquired a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH), purchasing 63,058 shares valued at approximately $2.98 million, representing a 0.13% stake in the company. Institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare exceeded quarterly expectations with $0.98 adjusted EPS and $265.71 million in revenue, though analyst ratings are mixed, with an average "Hold" rating and a price target of $70.75.

Prestige Consumer Healthcare's Medtech Products Inc. is voluntarily recalling nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops due to sterility concerns, although no active contamination has been identified. The FDA classified this as a Class II recall, meaning serious health consequences are unlikely. Consumers are advised to stop using the product and may seek refunds from retailers.